DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.

Author(s): Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS; ARIES study team.

Collaborators: Akil B, Applebaum J, Baril J, Bellos N, Cohen C, Cook P, Cuenca M, Berger D, Brar I, Brinson C, Carpio-Cedraro F, DeJesus E, Dretler R, Duggan J, Elion R, Gathe J, Godofsky E, Greenberg R, Hao R, Henry K, Khalsa A, Kort J, Kumar P, Lackey P, LaMarca A, Lucasti C, McDonald C, McLeroth P, Melendez-Rivera I, Mestre A, Morales-Ramirez J, Murphy D, Nahass R, Newman C, O'Brien W, O'Keefe P, Oldfield E, Overton E, Pearce D, Potter M, Rachlis A, Ramgopal M, Rashbaum B, Rhame F, Richmond G, Rodriguez J, Salvato P, Sanchez A, Santiago L, Sarria J, Sarria P, Schneider S, Scott R, Scribner A, Sepulveda G, Simon G, Siraj D, Slim J, Sloan L, Small C, Smith C, Squires K, Tashima K, Tebas P, Thompson M, Torees J, Trivedi V, Vanig T, Walmsley S, Ward D, Weinberg W, Weinert M, Young B.

Affiliation(s): Division of Infectious Diseases, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA. kathleen.squires@jefferson.edu

Publication date & source: 2010, AIDS. , 24(13):2019-27

BACKGROUND: Treatment simplification strategies involving induction with a ritonavir (RTV)-boosted (/r) protease inhibitor regimen followed by simplification (without RTV) are appealing because they may offer sustained virologic suppression while minimizing potential long-term adverse effects associated with RTV. METHODS: This open-label, randomized, noninferiority study enrolled 515 antiretroviral therapy-naive patients to receive abacavir/lamivudine plus atazanavir/RTV (ATV/r) followed by randomization at week 36 (N = 419) to maintain or discontinue RTV for an additional 48 weeks. Eligibility for randomization required confirmed HIV RNA level below 50 copies/ml and no virologic failure. Protocol-defined virologic failure after week 36 was confirmed rebound of HIV RNA level at least 400 copies/ml. The primary endpoint was the proportion of patients with HIV RNA level below 50 copies/ml at week 84 (time to loss of virologic response). This study is registered with ClinicalTrials.gov number NCT00440947. RESULTS: At week 84, noninferiority of ATV to ATV/r (95% confidence interval around the treatment difference -1.75 to 12.48%) was demonstrated with 181 of 210 (86%) patients in the ATV group and 169 of 209 (81%) in the ATV/r group maintaining HIV RNA level below 50 copies/ml. During the randomized phase (weeks 36-84), 10 versus 14% of patients in the ATV and ATV/r arms, respectively, experienced a drug-related grades 2-4 adverse event with hyperbilirubinemia being the most frequently reported (4 versus 10%). The overall rate of protocol-defined virologic failure was 2%; no patient had virus that developed a major protease inhibitor mutation. CONCLUSION: ATV in combination with abacavir/lamivudine is a potent and well tolerated regimen in patients who have achieved initial suppression on an induction regimen and represents a viable treatment simplification strategy.

Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017